Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
SBCH: Malt king weakening? - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Aug 2, 2002

    SBCH: Malt king weakening?

    GlaxoSmithKline Consumer Healthcare Ltd. (erstwhile SmithKline Beecham Consumer Healthcare) posted diappointing results for the June quarter. The company posted a never before 26% decline in the topline in 1QFY03. This resulted in the margins getting squeezed and the company finally finished the quarter with a significant 45% dip in bottomline.

    (Rs m) 2QFY02 2QFY03 Change 1HFY02 1HFY03 Change
    Net sales 2,121 1,561 -26.4% 3,968 3,416 -13.9%
    Other Income 70 39 -43.7% 153 80 -47.7%
    Expenditure 1,627 1,265 -22.3% 3,092 2,660 -14.0%
    Operating Profit (EBDIT) 494 296 -40.1% 875 756 -13.7%
    Operating Profit Margin (%) 23.3% 19.0%   22.1% 22.1%  
    Interest (net) (8) (8)   16 -5 -
    Depreciation 34 34 0.0% 67 68 1.5%
    Profit before Tax 538 310 -42.5% 946 773 -18.3%
    Tax 135 88 -34.9% 257 257 -0.2%
    Profit after Tax/(Loss) 403 222 -45.0% 688 516 -25.0%
    Net profit margin (%) 19.0% 14.2%   17.4% 15.1%  
    No. of Shares (eoy) (m) 45.4 45.4   45.4 45.4  
    Diluted Earnings per share* 35.5 19.6   30.3 22.8  
    Current P/e ratio   16.2     13.9  

    The results have surprised the analyst community. Though the company has not commented on the reasons for the sharp dip in topline, it seems that the dip has more to do with an inventory correction than anything else.

    Whatever the reasons, the poor results have shaken investor confidence towards the counter. GlaxoSmithKline Consumer anyway never got higher valuations owing to its one product category focus. The parent's other 100% subsidiary was always a cause for concern. But the blip in quarterly results saw the stock price lose over 13% of value ever since the results were announced.

    Cost breakup
    (Rs m) 2QFY02 2QFY03 Change 1HFY02 1HFY03 Change
    Stock 2 (95) - (95) (115) 20.4%
    RM 733 567 -22.6% 1,473 1,184 -19.6%
    Finished goods 15 21 43.8% 32 32 2.2%
    Staff cost 179 207 15.7% 344 400 16.1%
    Advertising 152 184 21.6% 341 352 3.0%
    Other exps 523 344 -34.2% 948 746 -21.3%
    Patent and trademark 12 25 - 25 37 50.2%
    Def. Rev. exps. 12 12 - 24 25 1.2%
    Total 1,626.90 1,265 -22.3% 3,092 2,660 -14.0%

    The stock is trading at Rs 317, a P/E of 14x annualised 1HFY02 earnings. We are reworking our estimation for FY03 post the surprising 2QFY03 results. Having said that, GlaxoSmithKline Consumer has traditionally had a stable business growth and there seems no reason to suggest that it may not bounce back.



    Equitymaster requests your view! Post a comment on "SBCH: Malt king weakening? ". Click here!


    More Views on News

    GSK Consumer: On the Recovery Path (Quarterly Results Update - Detailed)

    Jun 20, 2017

    While GSK consumer reported muted revenue growth, volumes are seen to be recovering.

    GSK Consumer: Price Hike Hurts Volumes (Quarterly Results Update - Detailed)

    Nov 30, 2016

    GSK Consumer Healthcare declared results for the quarter ended September 2016. The revenues dropped by 1.3% during the quarter as compared to a year ago; while the profits declined by 16.6% YoY during the quarter.

    GSK Consumer: Slowdown in demand impacts sales (Quarterly Results Update - Detailed)

    Oct 5, 2016

    GSK Consumer Healthcare has announced the first quarter results of the financial year 2016-2017 (1QFY17). The company's sales declined by 1.4% YoY while net profit rose by 2.9% YoY during the quarter.

    Apex frozen food Ltd. (IPO)

    Aug 21, 2017

    Should you subscribe to the IPO of Apex Frozen Foods Ltd?

    GSK Consumer: A Forgetful Year (Quarterly Results Update - Detailed)

    Jun 1, 2016

    GSK Consumer Healthcare announced its results for the quarter and year ended March 2016. During the quarter, sales and profit came in lower by 9% YoY and 8% YoY respectively.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 23, 2017 (Close)


    • Track your investment in GSK CONSUMER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts